24 results for “2026”
Europe’s dedicated medical cannabis education series for clinicians and industry professionals announces two autumn events — 4 November at Mainhaus, Frankfurt, and 26 November at Conway Hall, London
UK imports of the medical cannabis and the range of products available to patients both doubled in 2025.
Clinicians, scientists and patients explored whether medical cannabis could help address longstanding inequalities in women’s health.
The team at Prohibition Partners shares how they think things will shape up for medical cannabis in 2026.
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval. After seven years of endeavour, and an investment of over $250m, […]
Switzerland has approved a draft proposal to establish a fully commercial adult-use cannabis market.
The French ANSM assured at the beginning of the year that cannabis-based treatments would be available by 2025.
Ask any UK cannabis clinic which conditions bring people through the door, and ADHD will reliably be near the top of the list. Despite this demand, the published literature on […]
Findings point to differences in risk perception, communication and confidence discussing cannabis in cancer care.
The study is evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN).
Since launching its legal support helpline, Releaf Cannabis Clinic has received increasing reports from patients experiencing stigma and discrimination.
Germany has voted to ban medical cannabis flower from its statutory health insurance scheme.
Inhaled cannabis was associated with ‘large, sustained, and statistically robust improvements’ in pain and disability.
France’s incoming generalised medical cannabis framework has edged closer to clearing its last remaining hurdle.
Introducing The Medical Cannabis Employer Handbook
Pharmacist independent prescribers accounted for 61.9% of the total items prescribed between January 2019 and May 2025.
France’s medical cannabis experiment showed treatment was effective in reducing opioid use across four indications.
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market.
Curaleaf Laboratories, one of the UK’s leading manufacturers and distributors of EU-GMP medical cannabis products and Herdade das Barrocas (HDB), a Portuguese cultivator known for its cannabis genetics and cultivation expertise, […]
We take a closer look at the data behind medical cannabis prescribing to examine what it can reliably show us.
Exilby® has received market authorisation in Germany and Austria, with UK approval expected by the end of the year.
The development puts VER-01 in prime position to become the first FDA-approved cannabis-derived medicine for pain.
Medical cannabis has been legal in the UK since 2018, but for many patients, taking or carrying their prescribed medication in public still comes with uncertainty. Since launching its legal […]
The former heavyweight boxing contender revealed he is using prescribed medical cannabis to manage chronic pain.
